GURUFOCUS.COM » STOCK LIST » Latin America » Argentina » BUE » Biogen Inc (BUE:BIIB) » Definitions » Days Sales Outstanding
Switch to:

Biogen (BUE:BIIB) Days Sales Outstanding

: 67.81 (As of Dec. 2022)
View and export this data going back to 2019. Start your Free Trial

Biogen's average Accounts Receivable for the three months ended in Dec. 2022 was ARS316,936 Mil. Biogen's Revenue for the three months ended in Dec. 2022 was ARS426,502 Mil. Hence, Biogen's Days Sales Outstanding for the three months ended in Dec. 2022 was 67.81.

The historical rank and industry rank for Biogen's Days Sales Outstanding or its related term are showing as below:

BUE:BIIB' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.79   Med: 61.65   Max: 73.52
Current: 72.52

During the past 13 years, Biogen's highest Days Sales Outstanding was 73.52. The lowest was 39.79. And the median was 61.65.

BUE:BIIB's Days Sales Outstanding is ranked worse than
53.73% of 1018 companies
in the Drug Manufacturers industry
Industry Median: 69.35 vs BUE:BIIB: 72.52

Biogen's Days Sales Outstanding increased from Dec. 2021 (67.04) to Dec. 2022 (67.81).


Biogen Days Sales Outstanding Historical Data

The historical data trend for Biogen's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Days Sales Outstanding
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 49.65 51.26 56.22 63.77 59.52

Biogen Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Days Sales Outstanding Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 67.04 69.68 67.09 67.65 67.81

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biogen Days Sales Outstanding Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Biogen's Days Sales Outstanding falls in comparison to its industry or sector. The grey bar indicates the Days Sales Outstanding's extreme value range as defined by GuruFocus.



Biogen Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Biogen's Days Sales Outstanding for the fiscal year that ended in Dec. 2022 is calculated as

Days Sales Outstanding (A: Dec. 2022 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2021 ) + Accounts Receivable (A: Dec. 2022 )) / count ) / Revenue (A: Dec. 2022 )*Days in Period
=( (198112.07884103 + 358167.45008951) / 2 ) / 1705570.4628069*365
=278139.76446527 / 1705570.4628069*365
=59.52

Biogen's Days Sales Outstanding for the quarter that ended in Dec. 2022 is calculated as:

Days Sales Outstanding (Q: Dec. 2022 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Sep. 2022 ) + Accounts Receivable (A: Dec. 2022 )) / count ) / Revenue (A: Dec. 2022 )*Days in Period
=( (275704.58591268 + 358167.45008951) / 2 ) / 426501.5881987*365 / 4
=316936.01800109 / 426501.5881987*365 / 4
=67.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biogen  (BUE:BIIB) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


Biogen Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Biogen's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (BUE:BIIB) Business Description

Biogen logo
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (BUE:BIIB) Headlines